Current status of renin–aldosterone angiotensin system-targeting anti-hypertensive drugs as therapeutic options for Alzheimer's disease
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Hypertension is a modifiable risk factor for Alzheimer's disease (AD) and other dementias. Yet, despite this well-documented association, few of the current strategies to treat AD are directed at this possible target. The renin-aldosterone angiotensin system (RAAS) is a centrally active modifiable pathway that is involved in cerebral blood flow regulation. Currently, three classes of RAAS-targeting drugs are licensed for treatment of peripheral hypertension--angiotensin-converting enzyme inhibitors (ACE-Is), angiotensin II receptor blockers (ARBs) and direct renin inhibitors (DRIs). All of these are generally well tolerated and have been shown to offer varying degrees of protection on aspects of cognition and dementia, thus making them an attractive therapeutic option for AD. AREAS COVERED: This review summarises existing evidence regarding the plausibility of using RAAS-targeting drugs as a strategy to treat AD and highlights unresolved aspects to such approaches, namely the potential impact of altering angiotensin II-mediated processes in the central nervous system. EXPERT OPINION: Continued biochemical research of the RAAS pathway in combination with formal investigation of current RAAS-modifying drugs in randomised clinical trials is now necessary to determine their therapeutic value in AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer disease in the United States (2010–2050) estimated using the 2010 census
Hebert, L. E., Weuve, J., Scherr, P. A., & Evans, D. A. (2013) · Neurology · doi:10.1212/wnl.0b013e31828726f5 · Cited by 2,642
Alzheimer’s disease: Clinical trials and drug development
Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., & Kivipelto, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70119-8 · Cited by 1,217 · cited 1×
“However despite the long-term recognition of interactions between cardiovascular risk factors, cerebrovascular disease and AD, none of the currently licensed AD therapies and few of the current therapeutic strategies being explored for AD [14] attempt at targeting any of these interactions.”
Midlife blood pressure and dementia: the Honolulu–Asia aging study☆
Launer, L. J., Ross, G. W., Petrovitch, H., Masaki, K., Foley, D., White, L. R., & Havlik, R. J. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00096-8 · Cited by 1,008 · cited 1×
“In humans, in contrast, the association with hypertension appears more complex, likely confounded by protective effects of hypertension treatments [28,29], and as a result the underlying mechanisms remain poorly understood.”
BackgroundForette, F. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.18.2046 · Cited by 898 · cited 3×
“These include but are not restricted to: i) inclusion of oversimplistic grouping of anti-hypertensive drugs (e.g., grouping of diuretics/CCBs and ACE-Is/ARBs which while making sense from a hypertension perspective may not be sensible from the point of view of AD-related mechanisms -- see Ref.”
BackgroundPeters, R., Beckett, N., Forette, F., Tuomilehto, J., Clarke, R., Ritchie, C., Waldman, A., Walton, I., Poulter, R., Ma, S., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70143-1 · Cited by 770 · cited 1×
“[57] reported that aliskiren did not significantly reduce rates of dementia in people over Current status of RAS-targeting anti-hypertensive drugs as therapeutic options for AD”
BackgroundDoughan, A. K., Harrison, D. G., & Dikalov, S. I. (2008) · Circulation Research · doi:10.1161/circresaha.107.162800 · Cited by 710
Li, N.-C., Lee, A., Whitmer, R. A., Kivipelto, M., Lawler, E., Kazis, L. E., & Wolozin, B. (2010) · BMJ · doi:10.1136/bmj.b5465 · Cited by 486
Petrovitch, H., White, L. R., Izmirilian, G., Ross, G. W., Havlik, R. J., Markesbery, W., Nelson, J., Davis, D. G., Hardman, J., Foley, D. J., et al. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00106-8 · Cited by 468 · cited 1×
“Yet, there appears to be mounting evidence of a more intimate relationship between prior hypertension and levels of AD-related brain pathology [30-33], reinforcing the potential for hypertension to be treated as a modifiable risk factor for the prevention of AD.”
BackgroundDistinguishing Alzheimer’s disease from other major forms of dementia
Karantzoulis, S., & Galvin, J. E. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.155 · Cited by 385 · cited 1×
“This mixture of neuropathology confers overlapping cognitive manifestations, which understandably makes diagnosis, based on physical examination and cognitive assessments, quite challenging (Figure 1) [1].”
BackgroundPathology and pathogenesis of vascular cognitive impairment—a critical update
Jellinger, K. A. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00017 · Cited by 353 · cited 1×
“Cortical VaD usually has an abrupt onset and stepwise progression in cognitive decline, whereas subcortical VaD is more insidious and progresses steadily as seen in AD [4].”
BackgroundAβ-degrading enzymes: potential for treatment of Alzheimer disease
Miners, J. S., Barua, N., Kehoe, P. G., Gill, S., & Love, S. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3182345e46 · Cited by 265
Self-citationRisk Factors for β-Amyloid Deposition in Healthy Aging: Vascular and Genetic Effects
Rodrigue, K. M., Rieck, J. R., Kennedy, K. M., Devous, M. D., Diaz-Arrastia, R., & Park, D. C. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.1342 · Cited by 249
Anderson, C., Teo, K., Gao, P., Arima, H., Dans, A., Unger, T., Commerford, P., Dyal, L., Schumacher, H., Pogue, J., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70250-7 · Cited by 216
Power, M. C., Weuve, J., Gagne, J. J., McQueen, M. B., Viswanathan, A., & Blacker, D. (2011) · Epidemiology · doi:10.1097/ede.0b013e31822708b5 · Cited by 213 · cited 4×
“Considerable epidemiological evidence now links vascular disorders (hypertension), decreased systolic or diastolic blood pressure and decreased CBF with the incidence of AD [12].”
BackgroundInfluentialDavies, N. M., Kehoe, P. G., Ben-Shlomo, Y., & Martin, R. M. (2011) · Journal of Alzheimer’s Disease · doi:10.3233/jad-2011-110347 · Cited by 212 · cited 2×
“Anti-hypertensive therapies targeting RAAS function (ACE-Is and ARBs -- not DRIs, since there is limited evidence most likely due to the short time they have been in use) are associated with lower incidence of AD in UK-based [37] and US-based patients [38].”
BackgroundResultSelf-citationExamination of the current top candidate genes for AD in a genome-wide association study
Feulner, T. M., Laws, S. M., Friedrich, P., Wagenpfeil, S., Wurst, S. H. R., Riehle, C., Kuhn, K. A., Krawczak, M., Schreiber, S., Nikolaus, S., et al. (2010) · Molecular Psychiatry · doi:10.1038/mp.2008.141 · Cited by 128 · cited 1×
“Furthermore, a number of studies have shown that variants of the ACE gene are associated with increased risk of AD [69] and earlier ages at onset, and ACE variants, although not significant in large haplotype studies [70], were close to genome-wide significance in some of the most recent largescale genome-wide associa…”
BackgroundDong, Y.-F., Kataoka, K., Toyama, K., Sueta, D., Koibuchi, N., Yamamoto, E., Yata, K., Tomimoto, H., Ogawa, H., & Kim-Mitsuyama, S. (2011) · Hypertension · doi:10.1161/hypertensionaha.111.173534 · Cited by 109
Lithell, H., Hansson, L., Skoog, I., Elmfeldt, D., Hofman, A., Olofsson, B., Trenkwalder, P., & Zanchetti, A. (2004) · Journal of Hypertension · doi:10.1097/01.hjh.0000133730.47372.4c · Cited by 104 · cited 1×
“Furthermore, the double-blind randomised trial of candesartan (ARB), named study on cognition and prognosis in the elderly [50], the ongoing telmisartan alone and in combination with ramipril global endpoint trial and the telmisartan randomised assessment study in ACE intolerant subjects with cardiovascular disease tr…”
BackgroundHajjar, I., Hart, M., Chen, Y.-L., Mack, W., Milberg, W., Chui, H., & Lipsitz, L. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.1391 · Cited by 84
A Multi-Center Study of ACE and the Risk of Late-Onset Alzheimer's Disease
Belbin, O., Brown, K., Shi, H., Medway, C., Abraham, R., Passmore, P., Mann, D., Smith, A. D., Holmes, C., McGuinness, B., et al. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-101914 · Cited by 34 · cited 1×
“Furthermore, a number of studies have shown that variants of the ACE gene are associated with increased risk of AD [69] and earlier ages at onset, and ACE variants, although not significant in large haplotype studies [70], were close to genome-wide significance in some of the most recent largescale genome-wide associa…”
BackgroundSelf-citationAntihypertensive Medication Use and Incident Alzheimer Disease: The Cache County Study
Khachaturian, A. S. (2006) · Archives of Neurology · doi:10.1001/archneur.63.5.noc60013 · Cited by 3 · cited 2×
“Furthermore non-RAAS-targeting anti-hypertensive drugs including CCBs [39] and KSDs [40] appear to decrease the incidence of AD.”
Background
Cited by
Cerebrovascular disease in ageing and Alzheimer’s disease
Love, S., & Miners, J. S. (2016) · Acta Neuropathologica · doi:10.1007/s00401-015-1522-0 · Cited by 299
“The therapeutic potential of inhibiting the renin-angiotensin system in AD is attracting a great deal of interest and clinical investigation [4, 77, 79, 80, 119].”
BackgroundAndrieu, S., Coley, N., Lovestone, S., Aisen, P. S., & Vellas, B. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00153-2 · Cited by 293
The biological pathways of Alzheimer disease: a review
Calabrò, M., Department of Biomedical and Dental Sciences and Morphofunctional Imaging, U. O. M., Rinaldi, C., Santoro, G., & Crisafulli, C. (2021) · AIMS Neuroscience · doi:10.3934/neuroscience.2021005 · Cited by 265
Kehoe, P. G., Wong, S., AL Mulhim, N., Palmer, L. E., & Miners, J. S. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0217-7 · Cited by 203
“In AD, there is growing recognition that re-positioning of brain-penetrating ARBs and ACEIs may have clinical benefits in AD [64].”
BackgroundSelf-citationKehoe, P. G. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-171119 · Cited by 133
Self-citation
Metadata
- Authors
- Ashby, E. L., & Kehoe, P. G.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2013-06-26
- Volume
- 22
- Issue
- 10
- Pages
- 1229-1242
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2013523985
- Cited by
- 54
- References
- 21
- FWCI
- 4.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.